BSE Live
Apr 20, 16:01Prev. Close
79.72
Open Price
79.72
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 20, 15:41Prev. Close
79.34
Open Price
80.93
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
79.71 (5)
| Profit & Loss account of ZIM Laboratories (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 359.50 | 353.56 | 386.73 | 324.31 | 303.63 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue From Operations [Net] | 359.50 | 353.56 | 386.73 | 324.31 | 303.63 | |
| Total Operating Revenues | 375.64 | 365.47 | 396.53 | 329.49 | 303.63 | |
| Other Income | 5.62 | 4.69 | 6.43 | 4.51 | 2.45 | |
| Total Revenue | 381.26 | 370.16 | 402.96 | 334.00 | 306.08 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 155.00 | 177.70 | 164.98 | 160.61 | 152.82 | |
| Purchase Of Stock-In Trade | 11.58 | 7.80 | 17.39 | 9.41 | 6.92 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | 1.27 | -14.05 | 16.46 | -9.67 | -1.11 | |
| Employee Benefit Expenses | 56.41 | 50.81 | 46.47 | 38.63 | 34.48 | |
| Finance Costs | 11.39 | 6.92 | 5.58 | 8.31 | 10.89 | |
| Depreciation And Amortisation Expenses | 19.89 | 14.83 | 16.13 | 14.84 | 14.61 | |
| Other Expenses | 108.11 | 103.12 | 100.03 | 92.58 | 73.70 | |
| Total Expenses | 363.64 | 347.12 | 367.04 | 314.70 | 292.32 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 17.61 | 23.04 | 35.92 | 19.30 | 13.76 | |
| Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | -5.18 | |
| Profit/Loss Before Tax | 17.61 | 23.04 | 35.92 | 19.30 | 8.58 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 3.97 | 0.77 | 6.28 | 3.40 | 0.01 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | 1.42 | 5.45 | 4.63 | 2.88 | 2.95 | |
| Tax For Earlier Years | 0.48 | 0.06 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | 5.87 | 6.28 | 10.91 | 6.28 | 2.96 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 11.74 | 16.76 | 25.01 | 13.01 | 5.62 | |
| Profit/Loss From Continuing Operations | 11.74 | 16.76 | 25.01 | 13.01 | 5.62 | |
| Profit/Loss For The Period | 11.74 | 16.76 | 25.01 | 13.01 | 5.62 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 2.41 | 3.44 | 5.13 | 8.01 | 3.46 | |
| Diluted EPS (Rs.) | 2.41 | 3.44 | 5.13 | 8.01 | 3.46 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Equity Dividend Rate (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
26.11.2025
ZIM Lab Consolidated September 2025 Net Sales at Rs 88.71 crore, down 3.72% Y-o-Y
13.11.2025
ZIM Lab Standalone September 2025 Net Sales at Rs 88.39 crore, down 1.48% Y-o-Y
22.08.2025
ZIM Lab Standalone June 2025 Net Sales at Rs 71.43 crore, down 12.9% Y-o-Y
17.02.2025
ZIM Lab Standalone December 2024 Net Sales at Rs 95.40 crore, down 0.44% Y-o-Y
26.11.2025
ZIM Lab Consolidated September 2025 Net Sales at Rs 88.71 crore, down 3.72% Y-o-Y
13.11.2025
ZIM Lab Standalone September 2025 Net Sales at Rs 88.39 crore, down 1.48% Y-o-Y
22.08.2025
ZIM Lab Standalone June 2025 Net Sales at Rs 71.43 crore, down 12.9% Y-o-Y
17.02.2025
ZIM Lab Standalone December 2024 Net Sales at Rs 95.40 crore, down 0.44% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth